Top ▲

CTP synthase 1

Click here for help

Target id: 3215

Nomenclature: CTP synthase 1

Family: Nucleotide turnover

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 591 1p34.2 CTPS1 CTP synthase 1
Mouse - 591 4 56.52 cM Ctps1 cytidine 5'-triphosphate synthase 1
Rat - 591 5q36 Ctps1 CTP synthase 1
Previous and Unofficial Names Click here for help
cytidine 5'-triphosphate synthase | Ctps | cytidine 5'-triphosphate synthase | cytidine 5'-triphosphate synthetase | uridine triphosphate aminase
Database Links Click here for help
Alphafold
BRENDA
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
Pharos
UniProtKB
Wikipedia
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Human CTPS1 bound to inhibitor T35
PDB Id:  7MIG
Ligand:  compound 27 [PMID: 36449304]
Resolution:  2.9Å
Species:  Human
References:  1
Enzyme Reaction Click here for help
EC Number: 6.3.4.2

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound 27 [PMID: 36449304] Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Mm Inhibition 7.6 pIC50 4
pIC50 7.6 (IC50 2.6x10-8 M) [4]
compound 27 [PMID: 36449304] Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Rn Inhibition 7.6 pIC50 4
pIC50 7.6 (IC50 2.7x10-8 M) [4]
compound 27 [PMID: 36449304] Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.5 pIC50 4
pIC50 7.5 (IC50 3.2x10-8 M) [4]
View species-specific inhibitor tables
Immunopharmacology Comments
CTPS1 is critical for the proliferation of lymphoid cells [3]. Reduced expression/function of CTPS1 causes an immunodeficiency that is characterised by the failure of T and B cell proliferation in response to infection [2]. It is hypothesised that selective targeting of CTPS1 by pharmacological inhibitors may provide a mechanism to reduce aberrant immune cell proliferation in inflammatory/autoimmune conditions and haematological malignancies.

References

Show »

1. Lynch EM, DiMattia MA, Albanese S, van Zundert GCP, Hansen JM, Quispe JD, Kennedy MA, Verras A, Borrelli K, Toms AV et al.. (2021) Structural basis for isoform-specific inhibition of human CTPS1. Proc Natl Acad Sci U S A, 118 (40): e2107968118. [PMID:34583994]

2. Martin E, Minet N, Boschat AC, Sanquer S, Sobrino S, Lenoir C, de Villartay JP, Leite-de-Moraes M, Picard C, Soudais C et al.. (2020) Impaired lymphocyte function and differentiation in CTPS1-deficient patients result from a hypomorphic homozygous mutation. JCI Insight, 5 (5): e133880. [PMID:32161190]

3. Martin E, Palmic N, Sanquer S, Lenoir C, Hauck F, Mongellaz C, Fabrega S, Nitschké P, Esposti MD, Schwartzentruber J et al.. (2014) CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation. Nature, 510 (7504): 288-92. [PMID:24870241]

4. Novak A, Laughton D, Lane R, Blackham E, Thomas J, Chatzopoulou E, Wrigglesworth J, Quddus A, Ahmed S, Cousin D et al.. (2022) Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation. J Med Chem, 65 (24): 16640-16650. [PMID:36449304]

How to cite this page

Nucleotide turnover: CTP synthase 1. Last modified on 23/08/2023. Accessed on 20/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=3215.